ODYSSEUS Trademark

Trademark Overview


On Friday, January 31, 2025, a trademark application was filed for ODYSSEUS with the United States Patent and Trademark Office. The USPTO has given the ODYSSEUS trademark a serial number of 79422359. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, April 24, 2025. This trademark is owned by Trogenix Ltd. The ODYSSEUS trademark is filed in the Pharmaceutical Products, Computer & Software Products & Electrical & Scientific Products, and Computer & Software Services & Scientific Services categories with the following description:

Downloadable computer software programs; downloadable software, namely, lab information management systems; computer software platforms; downloadable software for remote diagnostics; machine learning software; machine learning software for use in genetic sequencing; algorithms, being computer software; bioinformatics software; imaging apparatus and instruments for use in the study of proteins and peptides in drug development; data processing software; downloadable computer applications in the fields of oncology, regenerative medicine, immunotherapy, recombinant protein production, immunology, cell engineering, CAR-T, viral vector engineering, genetic engineering, biopharmaceuticals, molecular biology, modulating therapeutics, assay systems, antigens and in vitro assays; software for predicting protein expression; software in the fields of genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, microbiology, pharmaceuticals, medicine, diagnostic preparations, v...

Pharmaceutical, medical or veterinary preparations and substances; RNA therapeutics; pharmaceutical preparations for use in targeted pharmaceutical therapies; pharmaceutical preparations and products for the treatment of neoplastic diseases; pharmaceutical preparations and products for the treatment of carcinomas and leukaemias; pharmaceutical preparations and products for the treatment of central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer, sarcomas, paediatric solid tumours, hepatocellular carcinoma, cancer of the eye and metastatic tumours; enhancers or super-enhancers for medical or clinical use; promoters for medical use; synthetic super enhancers in gene expression cassettes for medical or clinical use; DNA sequences and RNA sequences for medical purposes; transgenes for medical purposes; pharmaceutical preparations for use in regenerative medicines for treatment of fibrosis, age-associate...

Design, development and maintenance of software in the fields of genetic sequencing, genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, synthetic biology, engineering biology, DNA assembly, DNA synthesis, genome editing, protein engineering, antibody engineering, microbiology, pharmaceuticals, medicine, diagnostic preparations, immunopharmaceuticals, vaccines, medicine, health, microorganisms, molecular sciences, bacteria, biochemicals, cells, stem cells, organoids, cancer stem cells, clinical trials, physiology, genetics, genomics, microbiome, metabolomics, metagenomics, proteomics, glycomics, biochemistry, therapeutics, targeted pharmaceutical therapies, bacteriology, gene expression, DNA sequencing, DNA screening, RNA sequencing, RNA screening, transgenes, biochemical reagents and biochemical assays; design, development and maintenance of software algorithms in the fields of biotechnology and modulating therapeutics; design, development and maintenance...
odysseus

General Information


Serial Number79422359
Word MarkODYSSEUS
Filing DateFriday, January 31, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, April 24, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDownloadable computer software programs; downloadable software, namely, lab information management systems; computer software platforms; downloadable software for remote diagnostics; machine learning software; machine learning software for use in genetic sequencing; algorithms, being computer software; bioinformatics software; imaging apparatus and instruments for use in the study of proteins and peptides in drug development; data processing software; downloadable computer applications in the fields of oncology, regenerative medicine, immunotherapy, recombinant protein production, immunology, cell engineering, CAR-T, viral vector engineering, genetic engineering, biopharmaceuticals, molecular biology, modulating therapeutics, assay systems, antigens and in vitro assays; software for predicting protein expression; software in the fields of genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, microbiology, pharmaceuticals, medicine, diagnostic preparations, vaccines, medicine, health, microorganisms, molecular sciences, bacteria, biochemicals, cells, stem cells, organoids, cancer stem cells, clinical trials, physiology, genetics, genomics, microbiome, metabolomics, metagenomics, proteomics, glycomics, biochemistry, therapeutics, targeted pharmaceutical therapies, bacteriology, gene expression, DNA sequencing, DNA screening, RNA sequencing, RNA screening, transgenes, biochemical reagents and biochemical assays; downloadable computer software for scientific analysis of genetic sequences; software algorithms in the fields of biotechnology and modulating therapeutics; software as a medical device; artificial intelligence software in the field of healthcare.
Goods and ServicesPharmaceutical, medical or veterinary preparations and substances; RNA therapeutics; pharmaceutical preparations for use in targeted pharmaceutical therapies; pharmaceutical preparations and products for the treatment of neoplastic diseases; pharmaceutical preparations and products for the treatment of carcinomas and leukaemias; pharmaceutical preparations and products for the treatment of central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer, sarcomas, paediatric solid tumours, hepatocellular carcinoma, cancer of the eye and metastatic tumours; enhancers or super-enhancers for medical or clinical use; promoters for medical use; synthetic super enhancers in gene expression cassettes for medical or clinical use; DNA sequences and RNA sequences for medical purposes; transgenes for medical purposes; pharmaceutical preparations for use in regenerative medicines for treatment of fibrosis, age-associated disorders, senescence, rejuvenation, neurological disease, tissue injury and tissue repair; gene therapy pharmaceuticals; pharmaceutical preparations being vectors; biotechnological preparations for medical use; biological compounds for use in the targeted pharmaceutical therapies; proteins with diagnostic and therapeutic uses; chemical and enzyme preparations for medical or veterinary purposes; reagents and substances for use in testing for medical and veterinary purposes; drug delivery agents that facilitate the delivery of pharmaceutical preparations; clinical medical reagents; diagnostic and testing preparations for clinical, medical and medical laboratory use; pharmaceuticals in the field of modulating therapeutics; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for the treatment of cancer; biological preparations for use in cell cultures for medical purposes; diagnostic biomarker reagents for medical purposes; cells for medical or clinical use; immune cells; target antigens for medical use; vaccine preparations; therapeutic vaccines.
Goods and ServicesDesign, development and maintenance of software in the fields of genetic sequencing, genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, synthetic biology, engineering biology, DNA assembly, DNA synthesis, genome editing, protein engineering, antibody engineering, microbiology, pharmaceuticals, medicine, diagnostic preparations, immunopharmaceuticals, vaccines, medicine, health, microorganisms, molecular sciences, bacteria, biochemicals, cells, stem cells, organoids, cancer stem cells, clinical trials, physiology, genetics, genomics, microbiome, metabolomics, metagenomics, proteomics, glycomics, biochemistry, therapeutics, targeted pharmaceutical therapies, bacteriology, gene expression, DNA sequencing, DNA screening, RNA sequencing, RNA screening, transgenes, biochemical reagents and biochemical assays; design, development and maintenance of software algorithms in the fields of biotechnology and modulating therapeutics; design, development and maintenance of software in the fields of oncology, regenerative medicine, immunotherapy, recombinant protein production, immunology, cell engineering, CAR-T, viral vector engineering, genetic engineering, biopharmaceuticals, molecular biology, modulating therapeutics, assay systems, antigens and in vitro assays; design, development and maintenance of machine learning software for use in bioinformatics, genetic sequencing, predicting protein expression, cell suppression and analysis of cell behaviours; gene regulation control services; gene regulatory network analysis; analysis, management and review of technical data; development and testing of computing methods, algorithms and software; design, development and maintenance of machine learning software; research in the field of artificial intelligence software; design and development of lab information management systems; design and development of software testing methods; providing non-downloadable software for controlling, monitoring, programming and adjusting environmental conditions for cell culture, cell therapy or gene therapy; software as a service [SaaS] platforms and tools for collecting and interpreting clinical data; development and testing of computing methods, algorithms and software; platform as a service services; computer aided analysis services in the field of pharmaceuticals; database development and maintenance services; design and development of computer platforms; research and development services in the fields of pharmacogenetics, targeted pharmaceutical therapies and drug delivery platforms; research and development services in the field of regenerative medicines for the treatment of fibrosis, age-associated disorders, senescence, rejuvenation, neurological disease, tissue injury and tissue repair; research and development services in the fields of pharmaceuticals, immunopharmaceuticals, neoplastic diseases, modulating therapeutics, enhancers, super-enhancers, promoters, synthetic super enhancers in gene expression, DNA sequences, RNA sequences, fluorescent reporters, genetic cassettes, transgenes, gene therapy, drug delivery agents, vectors, diagnostic biomarker reagents, cell cultures, cell engineering, immunology and vaccines; research and development services in the fields of synthetic biology, engineering biology, DNA assembly, DNA synthesis, genome editing, protein engineering and antibody engineering; research and development services for the treatment of cancers, carcinomas, leukaemias, central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer, sarcomas, paediatric solid tumours, hepatocellular carcinoma, cancer of the eye and metastatic tumours; research and development services for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological, biochemical, biomedical, bacteriological and pharmacological research, analysis, engineering and development services; biological laboratory services; cell engineering services, namely cell suppression, cell activation, and cell programming and reprogramming; culturing of cells for scientific or medical research purposes; contract research services relating to enhancers, and super-enhancers and promoters; drug development services; development of gene-based medicines; providing information about medical research in the fields of biopharmaceuticals, immunology, cell engineering and immunoassays; scientific services relating to the isolation and cultivation of human tissues and cells; laboratory services namely, research, analysis, characterising, development and production of therapeutics for the treatment of neoplastic diseases, carcinomas, leukaemias, central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer, sarcomas, paediatric solid tumours, hepatocellular carcinoma, cancer of the eye and metastatic tumours; genetic engineering services; genetic sequencing and genotyping services; RNA sequencing services; analysis services regarding the safety and efficacy of new pharmaceuticals; diagnostic services in the field of immunology; polymerase chain reaction [PCR] services; preparation of reports in the field of biotechnology; testing of human tissues and stem cells for scientific or medical research purposes; use of biomarkers to investigate human immune response for medical purposes; design, research, analysis and engineering services relating to genetic cassettes; design and engineering services relating to genomic safe harbours, recombination sites, minimal promoters, insulators, splicing control elements, gene terminators, UTRs, capsids, fusion linkers, translational control elements and transcriptional units; RNA sequence optimisation services; evaluation services relating to RNA quality; translational control services in the field of gene expression; design of therapeutic payloads; consultancy, information and advisory services relating to all of the aforesaid services.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 24, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus.
US Class Codes021, 023, 026, 036, 038
Class Status Code6 - Active
Class Status DateThursday, April 24, 2025
Primary Code009
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, April 24, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTrogenix Ltd
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressGB

Trademark Events


Event DateEvent Description
Thursday, April 24, 2025SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, April 25, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 25, 2025APPLICATION FILING RECEIPT MAILED